Gliatilin 1000 mg 4 ml 3 pcs. solution for infusion and intramuscular injection

Composition and release form

in a blister pack 14 pcs.; in a cardboard pack 1 package.

in ampoules of 4 ml; in a blister pack there are 1 or 3 ampoules, in a cardboard pack there is 1 ampoules.

Operating principle

The main component Choline alfoscerate stimulates central cholinergic receptors, improves cerebral circulation and metabolism in the central nervous system. This compound ensures the production of special components in neuronal membranes - phosphatidylcholine and acetylcholine. When taking Choline alfoscerate, reticular formation is stimulated and the plasticity of neuronal membranes increases.

The combination of the described effects leads to the following improvements in the patient’s condition:

1. Increased mood;
2. The emergence of emotional stability;
3. Optimization of behavioral reactions;
4. Increasing concentration, ability to perceive, remember and reproduce information received from outside.

In case of TBI, the main component of choline alfoscerate improves the bioelectrical activity of the brain and stimulates blood flow in the affected area. This helps reduce neurological symptoms.

In the body, choline alfoscerate is broken down into 2 components:

• glycerophosphate;
• choline

The substance is absorbed into tissues by 88%, concentrated mainly in the brain. It is excreted from the body by the lungs (85% is exhaled in the form of carbon dioxide) and by the kidneys and liver (up to 15%).

Pharmacodynamics

Improves the transmission of nerve impulses in cholinergic neurons; has a positive effect on the plasticity of neuronal membranes and receptor function. Improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in case of traumatic brain injury.

It has a preventive and corrective effect on such pathogenetic factors of involutional psychoorganic syndrome as changes in the phospholipid composition of neuronal membranes and a decrease in cholinergic activity.

Experimental studies have shown that Gliatilin stimulates the dose-dependent release of acetylcholine under physiological conditions of neurotransmission.

When ingested, it is broken down by enzymes into choline and glycerophosphate.

Gliatilin, on the one hand, being a choline donor, increases the synthesis of acetylcholine and has a positive effect on neurotransmission, on the other hand, glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), as a result, both have a positive effect on membrane elasticity and receptor function, which improves synaptic transmission.

Thus, pharmacodynamic studies have shown that Gliatilin acts on the synaptic, incl. cholinergic neurotransmission; plasticity of the neuronal membrane; receptor function.

Gliatilin 1000 mg 4 ml 3 pcs. solution for infusion and intramuscular injection

pharmachologic effect

Nootropic drug.

Composition and release form Gliatilin 1000 mg 4 ml 3 pcs. solution for infusion and intramuscular injection

Solution - 1 amp. (3 ml):

• Active substance: choline alfoscerate - 1000 mg;
• Excipients: water for injection - up to 3 ml.

3 ml in ampoules of neutral colorless glass, type I. 3, 5 or 6 ampoules in a blister pack. 1 blister pack along with instructions for use in a cardboard box.

3 ampoules per blister pack. 2 blister packs each along with instructions for use in a cardboard box.

Description of the dosage form

Transparent colorless solution.

Directions for use and doses

The drug is administered intramuscularly or intravenously (drip, slowly) at a dose of 1000 mg (1 ampoule) per day for 10 days.

Doses and duration of treatment, if necessary and well tolerated, can be increased by the attending physician depending on the clinical picture, characteristics of the course of the disease, age and tolerability of the drug.

If adverse reactions occur, a temporary dose reduction is possible.

Children. There is no experience with the use of Gliatilin in children.

Pharmacodynamics

Improves the transmission of nerve impulses in cholinergic neurons; has a positive effect on the plasticity of neuronal membranes and receptor function. Improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in case of traumatic brain injury.

It has a preventive and corrective effect on such pathogenetic factors of involutional psychoorganic syndrome as changes in the phospholipid composition of neuronal membranes and a decrease in cholinergic activity.

Experimental studies have shown that Gliatilin stimulates the dose-dependent release of acetylcholine under physiological conditions of neurotransmission.

When ingested, it is broken down by enzymes into choline and glycerophosphate.

Gliatilin, on the one hand, being a choline donor, increases the synthesis of acetylcholine and has a positive effect on neurotransmission, on the other hand, glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), as a result, both have a positive effect on membrane elasticity and receptor function, which improves synaptic transmission.

Thus, pharmacodynamic studies have shown that Gliatilin acts on the synaptic, incl. cholinergic neurotransmission; plasticity of the neuronal membrane; receptor function.

Pharmacokinetics

Absorption when taken orally - 88%; easily penetrates the BBB, accumulates mainly in the brain (concentration in the brain reaches 45% of the level in the blood), lungs and liver; 85% is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Does not affect the reproductive cycle, does not have teratogenic or mutagenic effects.

Indications for use Gliatilin 1000 mg 4 ml 3 pcs. solution for infusion and intramuscular injection

• acute period of TBI with a predominantly brain stem level of damage (impaired consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damage);
• ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
• degenerative and involutional psychoorganic syndromes and consequences of cerebrovascular insufficiency, such as primary and secondary disorders of mnestic functions, characterized by memory impairment, confusion, disorientation, decreased motivation, initiative, and ability to concentrate;
• changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudomelancholy;
• multi-infarct dementia.

Contraindications

Hypersensitivity to the components of the drug.

Application Gliatilin 1000 mg 4 ml 3 pcs. solution for infusion and intramuscular administration during pregnancy and lactation

Contraindicated during pregnancy and lactation.

special instructions

Impact on the ability to drive vehicles and operate machinery

Caution should be exercised when driving vehicles or engaging in other activities that require increased concentration and/or speed of psychomotor reactions.

Overdose

Symptoms: nausea.

If this symptom appears, it is recommended to reduce the dose of the drug.

Side effects Gliatilin 1000 mg 4 ml 3 pcs. solution for infusion and intramuscular injection

Nausea (as a consequence of dopaminergic activation), in this case the dose of the drug should be reduced. Allergic reactions are possible.

As a rule, the drug is well tolerated even with long-term use.

Drug interactions

No drug interactions have been established.

Indications

acute period of TBI with a predominantly brain stem level of damage (impaired consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damage);

ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);

degenerative and involutional psychoorganic syndromes and consequences of cerebrovascular insufficiency, such as primary and secondary disorders of mnestic functions, characterized by memory impairment, confusion, disorientation, decreased motivation, initiative, and ability to concentrate;

changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudomelancholy;

multi-infarct dementia.

In what cases is Gliatilin prescribed?

Indications for taking this drug are functional disorders of the central nervous system caused by injuries or various diseases. Gliatilin is actively used in the treatment of the following pathologies:

1. Encephalopathy;
2. Senile, Alzheimer's, mixed dementia;
3. Huntington's chorea;
4. Senile pseudomelancholia.

In addition, Gliatilin is prescribed for the occurrence of the following cognitive disorders:

1. Confusion;
2. Memory impairment;
3. Reduced motivation and lack of concentration;
4. Disorientation in space and time.

The drug has proven itself well in recovery from traumatic brain injury (TBI) with damage at the brain stem level. Gliatilin is also used in therapy after an ischemic stroke.

Directions for use and doses

Injections: IM or IV (drops).

Capsules: orally, before meals.

Adults, in acute conditions: IM - at a dose of 1000 mg/day (1 amp.) or IV - 1000-3000 mg/day. For intravenous administration, the contents of 1 amp. (4 ml) diluted in 50 ml of saline, infusion rate - 60-80 drops per minute. The duration of treatment is usually 10 days, but if necessary, treatment can be continued until positive dynamics appear and it is possible to switch to oral capsules.

For chronic cerebrovascular insufficiency, changes in the emotional and behavioral sphere and multi-infarct dementia: orally - 400 mg (1 capsule) 3 times a day.

Duration of therapy is 3–6 months.

Instructions for use of Gliatilin

The instructions recommend long-term use of the drug, since restoration of brain function takes time. The minimum course is 3 months. It can be extended up to six months. As a rule, patients are prescribed the drug in the form of capsules for oral administration. But due to the fact that the capsules themselves are quite large, not every patient can absorb them, for example:

• child;
• a patient with a swallowing reflex disorder;
• patients who have suffered an ischemic stroke with a high degree of severity of damage.

In addition, unconscious and comatose patients are also unable to swallow the drug. In such cases, an alternative is prescribed - a solution for drip administration. 1 ampoule is diluted with 50 ml of saline solution. The rate of administration is no more than 80 drops per minute.

When prescribing capsules containing 400 mg of the active substance, the course consists of two to three doses per day. The medicine should be taken after meals. Each capsule is covered with a dense layer of soluble shell, which protects the active components from the aggressive environment of gastric juice and duodenum. Once in the large intestine, the coating disintegrates and releases the drug, from where it is easily absorbed into the bloodstream and reaches the brain. Therefore, the idea of ​​cutting the capsule and squeezing the contents into a puree-like food to make it easier to take is impractical. The acidic environment of the stomach will destroy all the benefits of the substance.